04:28 AM EST, 11/06/2025 (MT Newswires) -- Evommune (EVMN) said late Wednesday it priced its initial public offering of about 9.4 million common shares at $16 apiece, for about $150 million in expected gross proceeds.
IPO underwriters have a 30-day overallotment option to buy up to 1.4 million additional shares.
The clinical-stage biotechnology company expects its shares to start trading on the New York Stock Exchange under the symbol EVMN Thursday, while the IPO is expected to close Friday.